Catalent facing board shake-up pressure from activist investor Elliott

Catalent’s onerous year just got even more complicated. While the drugmaker stood out as the contract manufacturer to beat at the height of the COVID-19 pandemic, dwindling vaccine contracts, an FDA citation and executive turnover have afflicted Catalent in recent months.